diabetes mellitus type 1

Ozempic, Fiasp Now Available for the Treatment of Diabetes

By February 05, 2018

Both medications received approval from the FDA in 2017.

First Short-Acting Insulin Approved as a "Follow-On" Product

By December 11, 2017

The use of abbreviated pathways can reduce drug development costs so products can be offered at a lower price to patients.